Finance
France's Sanofi to acquire biotech firm Vicebio for $1.15 billion
Published by Global Banking & Finance Review®
Posted on July 22, 2025
1 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on July 22, 2025
1 min readLast updated: January 22, 2026
Sanofi acquires Vicebio for $1.15 billion to expand its vaccine portfolio, including a non-mRNA RSV vaccine and new Molecular Clamp technology.
(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.
Following the acquisition, Vicebio's non-mRNA candidate vaccine for treating respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) will be added to Sanofi's range.
The Vicebio deal includes a potential milestone payment of up to $450 million based on development and research achievements, and is expected to close in the fourth quarter of this year.
Sanofi will also obtain "Molecular Clamp" technology aimed at enabling quicker development of fully liquid combination vaccines that can be stored at standard refrigeration temperatures, eliminating the need for freezing or freeze-drying.
The British company is the latest in a string of acquisitions by Sanofi, which recently finalised an up to $9.5 billion deal for U.S.-based Blueprint Medicines Corporation.
Sanofi said that the acquisition will not impact its annual guidance.
(Reporting by Mateusz Rabiega; Editing by Jacqueline Wong, Kirsten Donovan)
An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.
A vaccine portfolio refers to the collection of vaccines that a pharmaceutical company develops, markets, and sells, aimed at preventing various diseases.
A milestone payment is a payment made when specific pre-defined events or achievements occur in a project, often used in contracts for development projects.
Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, particularly in young children and infants.
Human metapneumovirus (hMPV) is a virus that can cause respiratory infections, particularly in children and the elderly.
Explore more articles in the Finance category
